Continuing Education Activity

Meconium aspiration syndrome is a significant cause of neonatal respiratory distress that develops when newborns exposed to meconium-stained amniotic fluid exhibit symptoms not explained by other conditions. Although meconium passage is common in term and postterm infants, aspiration of this thick, debris-filled material can obstruct airways, trigger inflammation, inactivate surfactant, and impair ventilation. This course reviews how these processes contribute to hypoxemia, ventilation–perfusion mismatch, and complications such as persistent pulmonary hypertension of the newborn and air-leak syndromes, as well as the clinical presentations, which range from mild distress to severe respiratory failure. Therefore, timely recognition and intervention are critical.

This activity explores the pathophysiology, diagnostic evaluation, and supportive management of meconium aspiration syndrome. Participants will also refine their ability to identify risk factors, interpret clinical findings, and implement effective oxygenation and ventilatory strategies in collaboration with an interprofessional team. This activity for healthcare professionals is designed to enhance the learner's competence in identifying meconium aspiration syndrome, performing the recommended evaluation, making decisions regarding respiratory and cardiovascular support, and implementing an appropriate interprofessional approach to managing this condition to optimize outcomes for affected infants.

Objectives:

• Identify key pathophysiologic processes involved in meconium aspiration syndrome.
• Differentiate meconium aspiration syndrome from other causes of neonatal respiratory distress using clinical findings.
• Evaluate infants with suspected meconium aspiration syndrome using evidence-based tools.
• Coordinate interprofessional care among various teams to optimize outcomes in patients with meconium aspiration syndrome.

Introduction

Meconium is the earliest stool of a newborn. Occasionally, newborns pass meconium during labor or delivery, resulting in a meconium-stained amniotic fluid (MSAF). Meconium aspiration syndrome is a neonatal respiratory distress syndrome that occurs in a newborn with MSAF when respiratory symptoms cannot be attributed to another etiology.[1] The spectrum of manifestations associated with meconium aspiration is broad, ranging from mild distress to more severe respiratory failure. More life-threatening conditions have also been recognized to be associated with meconium aspiration syndrome, notably persistent pulmonary hypertension of the newborn (PPHN) and air leak syndromes.[2]

Etiology

Meconium aspiration syndrome develops when a newborn aspirates meconium-stained amniotic fluid. MSAF occurs relatively frequently but does not always lead to meconium aspiration syndrome.[3] Uterine stress related to hypoxia or infection can prompt early fetal passage of meconium. Unlike infant stool, meconium appears darker and thicker. Meconium forms through the accumulation of fetal cellular debris, including skin, gastrointestinal material, hair, and various secretions.[4] Aspiration of these substances obstructs the airways, initiates inflammatory responses, and inactivates surfactant. These combined effects impair ventilation and oxygenation, ultimately producing respiratory distress in the neonate.

Epidemiology

MSAF occurs more frequently in postterm newborns, and its incidence varies with gestational age. One study documented MSAF in 5.1%, 16.5%, and 27.1% of preterm, term, and postterm newborns, respectively.[5] Although MSAF remains necessary for diagnosing meconium aspiration syndrome, only 2% to 10% of infants born through meconium-stained amniotic fluid develop the condition.[3]  In preterm babies, MSAF is less likely and may represent asphyxia or some other indicator of intrauterine stress.[6]

The incidence of meconium aspiration syndrome also depends on access to care and rises in regions with frequent postterm deliveries. Lower rates have been observed in regions with high frequencies of early cesarean sections, despite other risks associated with cesarean delivery.[7] One study additionally reported a higher occurrence of MSAF among Black patients.[7][8] Some data suggest that providing intrapartum amnioinfusion for mothers with meconium-stained amniotic fluid reduces the rate of meconium aspiration syndrome in neonates.[9] However, this is not yet the standard of care at most centers.

Pathophysiology

The pathophysiology of meconium aspiration syndrome remains incompletely defined, yet 5 key processes shape current understanding: meconium passage, aspiration, airway obstruction, inflammation, and surfactant inactivation. These processes collectively reduce alveolar ventilation and worsen ventilation-perfusion mismatch, the primary cause of hypoxemia in infants with meconium aspiration syndrome. Persistent hypoxemia promotes pulmonary vascular constriction, elevating pulmonary vascular resistance and producing right-to-left shunting, changes that can precipitate PPHN.[10]

Meconium Passage

Fetal defecation rarely occurs between 20 and 34 weeks of gestation.[11] In utero passage becomes more frequent in late-term and postterm infants after 37 weeks.[12] Proposed contributors include increased peristalsis, anal sphincter relaxation, and alterations in vagal and sympathetic tone during fetal distress and hypoxia.

Aspiration

During delivery, fetal breathing typically moves amniotic fluid into and out of the lungs. When meconium stains the fluid, the aspiration risk increases. Hypoxia can intensify fetal gasping, resulting in greater inhalation of meconium-contaminated fluid.[13]

Airway Obstruction

Thick meconium combined with narrow fetal airways can obstruct airflow, functioning similarly to foreign body aspiration. A meconium plug may create a complete obstruction with distal lung collapse and atelectasis. Partial obstruction produces a ball-valve effect with air trapping and a heightened risk of air-leak syndromes, particularly pneumothorax. Recent evidence shows that obstruction does not consistently occur with MSAF and cannot fully account for meconium aspiration syndrome.[14]

Inflammation

Components of meconium activate inflammatory pathways that contribute to respiratory distress and cause chemical pneumonitis. Elevated levels of matrix metalloproteinase-8, interleukin-6, interleukin-8, interferon-gamma, and tumor necrosis factor-alpha have been documented in affected infants.[15][16]

Surfactant Inactivation

Inflammation and hydrolysis can alter and inactivate surfactant.[17] This leads to increased surface tension, poor compliance, and impaired oxygenation. Thus, further contributing to the respiratory distress seen in meconium aspiration syndrome.

History and Physical

Clinical History

Relevant historical features supporting a diagnosis of meconium aspiration syndrome include a term or postterm newborn, neonatal respiratory distress without an alternative explanation, and the presence of meconium-stained amniotic fluid. These elements create a clinical context that raises suspicion for meconium aspiration when respiratory compromise appears shortly after birth.[10]

Physical Examination Findings

Physical examination may reveal multiple findings consistent with meconium aspiration syndrome. Signs of postmaturity can include vernix loss, peeling skin, and long fingernails. Indicators of respiratory distress at birth often include bradycardia, hypoxemia, cyanosis, and tachypnea. Birth depression, reflected by a limp or nonvigorous infant, further supports concern. Meconium-stained amniotic fluid and visible meconium staining on the newborn's skin or umbilical cord reinforce the diagnostic impression.

Evaluation

Clinical features are key in diagnosing suspected meconium aspiration syndrome. This is crucial, as early interventions and management can be necessary for respiratory and cardiovascular support. In addition to clinical assessment, diagnostic studies used in the evaluation of meconium aspiration syndrome include:

• Chest radiograph (CXR): Early CXR findings are nonspecific, including streaky densities bilaterally. Later findings on CXR include hyperinflation, diaphragmatic flattening, and atelectasis. Pneumothorax can also be seen.
• Arterial blood gas (ABG): A diagnostic test used to assess the severity of respiratory failure and guide management (intubation, mechanical ventilation). In severe cases, ABG will show hypoxemic, hypercapnic, and respiratory acidosis. 
• Pulse oximetry: This assessment tool measures oxygenation and the degree of shunting (preductal and postductal differential).
• Echocardiography: An essential tool for assessing heart function and screening for signs of PPHN and right ventricular dysfunction. Echocardiography also helps identify cardiac anatomy and evaluate for any cardiac-level right-to-left shunting.
• Blood and tracheal cultures: Evaluation for sepsis and pneumonia is crucial in the context of neonatal distress. Often, empirical antibiotics are started; however, studies suggest that, while inflammatory markers are elevated, the correlation between elevated inflammatory markers and blood culture positivity is poor.[18]

Treatment / Management

Infants born through meconium-stained amniotic fluid should receive routine neonatal care while being closely monitored for signs of distress according to established neonatal resuscitation guidelines. The 2015 guidelines from the American Heart Association, the International Liaison Committee on Resuscitation, and the American Academy of Pediatrics no longer recommend routine endotracheal suctioning for nonvigorous infants with MSAF.[19][20][21] Continuous observation for clinical indicators of meconium aspiration syndrome remains essential to enable timely intervention. Meconium aspiration is a significant risk factor for birth asphyxia, which may necessitate therapeutic hypothermia.[22][23][22] However, this therapy may in turn worsen pulmonary hypertension, necessitating the need for extreme vigilance and close monitoring at a center capable of providing the full spectrum of therapies, eg, extracorporeal membrane oxygenation (ECMO).[24]

Management of meconium aspiration syndrome focuses primarily on supportive care, with early recognition and intervention improving outcomes and reducing morbidity and mortality. Effective management requires a coordinated interprofessional team, including obstetricians, midwives, neonatologists, respiratory therapists, nurses, pediatric pulmonologists, and pediatric cardiologists.

Oxygen therapy often becomes necessary, with a target oxygen saturation above 90% to prevent tissue hypoxia and support adequate oxygenation. Hypoxemia can trigger pulmonary vasoconstriction, increasing pulmonary vascular resistance and exacerbating PPHN. Ventilatory support may be required for refractory hypoxemia, carbon dioxide retention, or worsening respiratory distress, and also supports patients with PPHN or air-leak syndromes. No standardized ventilation strategy exists; monitoring oxygenation and performing serial arterial blood gases help optimize respiratory support. Severe, refractory cases may require ECMO for cardiorespiratory stabilization.

Surfactant therapy is not standard of care but may benefit cases in which surfactant inactivation contributes to respiratory compromise.[2][25] Some data suggest that surfactant may reduce the need for mechanical ventilation, among other benefits, but larger prospective trials are needed to confirm these findings.[26] Inhaled nitric oxide, a pulmonary vasodilator, can help manage pulmonary hypertension and PPHN, improving oxygenation and reducing right-to-left shunting. In severe cases, additional pulmonary vasodilators may also be used. A high-frequency oscillator can also help increase oxygenation by maintaining a high mean airway pressure. Inhaled nitric oxide may help avoid the need for ECMO by reducing pulmonary hypertension.

Differential Diagnosis

The differential diagnoses for meconium aspiration syndrome should consider other causes of newborn distress, including:

• Respiratory distress syndrome (more common in a preterm infant)
• Transient tachypnea of the newborn (usually resolves within 72 hours) 
• Sepsis/infection/pneumonia, any newborn with distress should be assessed for infections
• Congenital heart disease (usually diagnosed with an echocardiogram)

Prognosis

Mortality in meconium aspiration syndrome is close to 1.2% based on a large retrospective study in the United States. This is lower than the mortality reported in developing countries.[27] Most affected infants recover fully, with a favorable long-term prognosis and minimal lasting complications.

Complications

Short-term complications of meconium aspiration syndrome include:

• Hypoxic ischemic encephalopathy
• PPHN
• Air leak syndromes, particularly in late-term newborns [28]

Long-term complications of meconium aspiration syndrome include:

• Later development of reactive airway disease
• They are also at risk for neurodevelopmental impairment, which could also be related to prolonged intubation, mechanical ventilation, and prolonged oxygen need.

Consultations

Consultations that may be involved in the management of meconium aspiration syndrome include:

• Pediatric cardiology, if an echocardiogram is needed
• ECMO team, if needed, for cannulation

Deterrence and Patient Education

Meconium aspiration primarily affects term and postterm newborns delivered through meconium-stained amniotic fluid. The condition occurs in fewer than 10% of infants exposed to meconium-stained fluid. It represents a significant cause of neonatal respiratory distress, requiring prompt recognition and management. Clinicians should evaluate and rule out other potential causes, eg, neonatal infections, to ensure accurate diagnosis. Conversely, babies can have meconium aspiration syndrome without having a history of MSAF.[29]

Parental education plays a critical role, as management typically involves admission to the neonatal intensive care unit and focuses on supportive care. Early identification and timely intervention significantly improve outcomes, and most affected infants recover fully with minimal long-term complications.

Enhancing Healthcare Team Outcomes

Meconium aspiration syndrome occurs when a newborn inhales meconium-stained amniotic fluid, most often affecting term and postterm infants. Although fewer than 10% of infants exposed to meconium-stained fluid develop MAS, the condition represents a significant cause of neonatal respiratory distress. Pathophysiologic mechanisms include airway obstruction, inflammation, and surfactant inactivation, which contribute to hypoxemia and, in severe cases, persistent pulmonary hypertension of the newborn. Early recognition, differentiation from other causes of neonatal distress, and prompt supportive management are critical to improving outcomes. Most infants recover fully with timely intervention, but care often requires admission to a neonatal intensive care unit and coordination among multiple healthcare professionals.

Effective management of meconium aspiration syndrome demands coordinated skills and responsibilities across the interprofessional team. Physicians, general practitioners, and advanced practitioners must rapidly assess and diagnose infants, initiate respiratory support, and determine the need for advanced interventions. Nurses and respiratory therapists monitor oxygenation, implement ventilation strategies, and provide ongoing bedside care. Pharmacists ensure appropriate availability and dosing of medications, including surfactant or inhaled nitric oxide when indicated. Interprofessional communication and care coordination enhance patient safety, optimize treatment decisions, and improve team performance, ensuring that newborns receive timely, evidence-based, patient-centered care.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Fanaroff AA. Meconium aspiration syndrome: historical aspects. J Perinatol. 2008 Dec;28 Suppl 3:S3-7. [PubMed: 19057607]

2.

Vain NE, Batton DG. Meconium "aspiration" (or respiratory distress associated with meconium-stained amniotic fluid?). Semin Fetal Neonatal Med. 2017 Aug;22(4):214-219. [PubMed: 28411000]

3.

Whitfield JM, Charsha DS, Chiruvolu A. Prevention of meconium aspiration syndrome: an update and the Baylor experience. Proc (Bayl Univ Med Cent). 2009 Apr;22(2):128-31. [PMC free article: PMC2666857] [PubMed: 19381312]

4.

RAPOPORT S, BUCHANAN DJ. The composition of Meconium; isolation of blood-group-specific polysaccharides; abnormal compositions of meconium in meconium ileus. Science. 1950 Aug 04;112(2901):150-3. [PubMed: 15442281]

5.

Balchin I, Whittaker JC, Lamont RF, Steer PJ. Maternal and fetal characteristics associated with meconium-stained amniotic fluid. Obstet Gynecol. 2011 Apr;117(4):828-835. [PubMed: 21383642]

6.

Khare C, Abraham AR, Gautam G, Patel S. Meconium aspiration syndrome in a preterm newborn: An orphan disease. Trop Doct. 2024 Apr;54(2):207-208. [PubMed: 38031360]

7.

Saleh AM, Dudenhausen JW, Ahmed B. Increased rates of cesarean sections and large families: a potentially dangerous combination. J Perinat Med. 2017 Jul 26;45(5):517-521. [PubMed: 27824616]

8.

Alexander GR, Hulsey TC, Robillard PY, De Caunes F, Papiernik E. Determinants of meconium-stained amniotic fluid in term pregnancies. J Perinatol. 1994 Jul-Aug;14(4):259-63. [PubMed: 7965219]

9.

Davis JD, Sanchez-Ramos L, McKinney JA, Lin L, Kaunitz AM. Intrapartum amnioinfusion reduces meconium aspiration syndrome and improves neonatal outcomes in patients with meconium-stained fluid: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023 May;228(5S):S1179-S1191.e19. [PubMed: 37164492]

10.

Osman A, Halling C, Crume M, Al Tabosh H, Odackal N, Ball MK. Meconium aspiration syndrome: a comprehensive review. J Perinatol. 2023 Oct;43(10):1211-1221. [PubMed: 37543651]

11.

Abramovich DR, Gray ES. Physiologic fetal defecation in midpregnancy. Obstet Gynecol. 1982 Sep;60(3):294-6. [PubMed: 7121909]

12.

Matthews TG, Warshaw JB. Relevance of the gestational age distribution of meconium passage in utero. Pediatrics. 1979 Jul;64(1):30-1. [PubMed: 450556]

13.

Hooper SB, Harding R. Changes in lung liquid dynamics induced by prolonged fetal hypoxemia. J Appl Physiol (1985). 1990 Jul;69(1):127-35. [PubMed: 2394642]

14.

Ghidini A, Spong CY. Severe meconium aspiration syndrome is not caused by aspiration of meconium. Am J Obstet Gynecol. 2001 Oct;185(4):931-8. [PubMed: 11641681]

15.

Lee J, Romero R, Lee KA, Kim EN, Korzeniewski SJ, Chaemsaithong P, Yoon BH. Meconium aspiration syndrome: a role for fetal systemic inflammation. Am J Obstet Gynecol. 2016 Mar;214(3):366.e1-9. [PMC free article: PMC5625352] [PubMed: 26484777]

16.

Okazaki K, Kondo M, Kato M, Kakinuma R, Nishida A, Noda M, Taniguchi K, Kimura H. Serum cytokine and chemokine profiles in neonates with meconium aspiration syndrome. Pediatrics. 2008 Apr;121(4):e748-53. [PubMed: 18346989]

17.

Autilio C, Echaide M, Shankar-Aguilera S, Bragado R, Amidani D, Salomone F, Pérez-Gil J, De Luca D. Surfactant Injury in the Early Phase of Severe Meconium Aspiration Syndrome. Am J Respir Cell Mol Biol. 2020 Sep;63(3):327-337. [PubMed: 32348683]

18.

Periasamy U, Salvador A, Janeczko M. Pattern of Inflammatory Markers and Use of Antibiotics in Meconium Aspiration Syndrome: A Retrospective Cohort Study. Cureus. 2023 Sep;15(9):e44921. [PMC free article: PMC10560562] [PubMed: 37814760]

19.

Wyckoff MH, Aziz K, Escobedo MB, Kapadia VS, Kattwinkel J, Perlman JM, Simon WM, Weiner GM, Zaichkin JG. Part 13: Neonatal Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015 Nov 03;132(18 Suppl 2):S543-60. [PubMed: 26473001]

20.

Perlman JM, Wyllie J, Kattwinkel J, Wyckoff MH, Aziz K, Guinsburg R, Kim HS, Liley HG, Mildenhall L, Simon WM, Szyld E, Tamura M, Velaphi S., Neonatal Resuscitation Chapter Collaborators. Part 7: Neonatal Resuscitation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S204-41. [PubMed: 26472855]

21.

Dini G, Ceccarelli S, Celi F, Semeraro CM, Gorello P, Verrotti A. Meconium aspiration syndrome: from pathophysiology to treatment. Ann Med Surg (Lond). 2024 Apr;86(4):2023-2031. [PMC free article: PMC10990371] [PubMed: 38576961]

22.

Shah M, Sakr M, Balasundaram P. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 14, 2025. Neonatal Therapeutic Hypothermia. [PubMed: 33620791]

23.

Gillam-Krakauer M, Shah M, Gowen Jr CW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 5, 2024. Birth Asphyxia. [PubMed: 28613533]

24.

Sankaran D, Li JRA, Lakshminrusimha S. Meconium Aspiration Syndrome, Hypoxic-Ischemic Encephalopathy and Therapeutic Hypothermia-A Recipe for Severe Pulmonary Hypertension? Children (Basel). 2024 Jun 01;11(6) [PMC free article: PMC11202216] [PubMed: 38929252]

25.

Dargaville PA, Herting E, Soll RF. Neonatal surfactant therapy beyond respiratory distress syndrome. Semin Fetal Neonatal Med. 2023 Dec;28(6):101501. [PubMed: 38040584]

26.

Prasath A, Chotzoglou E, Ahmad A, Diaz E, Burchfield P, Brown LS, Nelson DB, Stumpf K, Kakkilaya V. Less invasive surfactant administration for meconium aspiration syndrome. BMJ Paediatr Open. 2025 May 12;9(1) [PMC free article: PMC12083396] [PubMed: 40355374]

27.

Singh BS, Clark RH, Powers RJ, Spitzer AR. Meconium aspiration syndrome remains a significant problem in the NICU: outcomes and treatment patterns in term neonates admitted for intensive care during a ten-year period. J Perinatol. 2009 Jul;29(7):497-503. [PubMed: 19158800]

28.

Luo L, Zhang M, Tang J, Li W, He Y, Qu Y, Mu D. Clinical characteristics of meconium aspiration syndrome in neonates with different gestational ages and the risk factors for neurological injury and death: A 9-year cohort study. Front Pediatr. 2023;11:1110891. [PMC free article: PMC10027737] [PubMed: 36959842]

29.

Padre J, Chen J, Devadas R, Rasheed A, O'Neill A, Martin C, Lissaman C, Thomas N. Meconium aspiration syndrome in the absence of meconium-stained amniotic fluid-A paradox. Acta Paediatr. 2024 Nov;113(11):2408-2410. [PubMed: 39037283]

Disclosure: Edouard Sayad declares no relevant financial relationships with ineligible companies.

Disclosure: Manan Shah declares no relevant financial relationships with ineligible companies.

Disclosure: Manuel Silva-Carmona declares no relevant financial relationships with ineligible companies.